PT-141 Subcutaneous Injection Pen - Inject+

Australia's First
PT-141
Subcutaneous Pen



What is PT-141?

PT-141, also known as Bremelanotide, is a synthetic peptide originally developed from the melanocortin hormone pathway.

It differs from conventional vasodilator-based agents because it acts on the central nervous system rather than directly on blood flow.

Research has focused on its ability to influence arousal signalling, mood, and energy balance through selective activation of melanocortin receptors (MC3R and MC4R) in the hypothalamus.

While it was first explored for sexual-function disorders, PT-141 has also been studied for autonomic modulation, fatigue, and motivation pathways, suggesting a broader neuro-peptide role beyond libido.

It is a Schedule 4 prescription-only compound and is dispensed in Australia solely through licensed compounding pharmacies following consultation with a registered prescriber.

What PT-141 Is Being Studied For?

Ongoing research is investigating PT-141’s potential in the areas of neuro-endocrine regulation, sexual function, and autonomic balance. Laboratory and clinical studies have explored:

Melanocortin receptor activation: Interaction with MC3R/MC4R influencing sympathetic tone, appetite control, and energy regulation. Neurovascular response: Central initiation of physiological arousal independent of nitric-oxide pathways. Mood and fatigue modulation: Early investigations into effects on dopaminergic and hypothalamic circuits related to motivation, focus, and alertness. Hormonal signalling: Possible influence on corticotropin-releasing hormone and downstream adrenal activity. Sexual health studies: Trials evaluating arousal, satisfaction, and receptivity in both male and female populations. These findings remain preliminary. PT-141 has not been approved by the TGA for any therapeutic indication in Australia, and all access occurs through prescription compounding under medical direction.

How It’s Dispensed?

When prescribed, PT-141 is compounded by an Australian-registered pharmacy and dispensed under pharmacist supervision.

Concentration: 3.5mg/mL
Volume: 3 mL pre-filled subcutaneous pen
Preservative system: Formulated in accordance with pharmacy sterility and stability standards
Temperature control: Shipped in insulated packaging with cold packs to maintain product integrity during transport

Storage & Handling

Keep refrigerated as directed by the dispensing pharmacy.
Do not freeze or expose to excessive heat.
If ice packs melt during transit, this does not affect integrity within the validated shipping window.
Follow all storage and handling instructions provided with your prescription.

Usage & Administration

Administration technique, dose volume, and frequency are determined individually by the prescribing clinician.

Follow all instructions printed on the pharmacy label. Do not self-administer unless you have received appropriate training and clinical clearance.

Typical practitioner-directed use may include:
Route: Subcutaneous injection via pre-filled PT-141 pen.
Injection site: Lower abdomen or outer thigh, as directed by the clinician.
Pattern: Intermittent systemic dosing aimed at triggering melanocortin-mediated libido pathways while avoiding overstimulation.
Cycle: Typically administered six times per month, with doses spaced roughly every 4–6 days, or as otherwise specified by the prescriber.
Timing: Given in the evening before bed to align with onset profile and reduce the impact of potential transient side effects such as flushing or nausea.
Technique: Clean the skin with an alcohol swab, inject the prescribed dose, and dispose of the needle safely after use.
Rotation: Alternate injection sites across the lower abdomen and thighs to minimise irritation and support comfort with repeated intermittent use.

All dosing parameters (including dose spacing, evening timing, and total course duration) are determined by the prescribing clinician based on goals, sensitivity, and individual response.

Safety & Precautions

Prescription-only; use only under medical supervision. Disclose all medical conditions, allergies, and concurrent medications before starting. May cause transient flushing, mild nausea, or headache in some individuals; report persistent symptoms to your clinician. Not recommended during pregnancy or breastfeeding. Do not combine with other vasoactive or centrally acting agents unless approved by a prescriber.

Research Context

PT-141 represents a class of peptides that target central melanocortin pathways, distinct from the peripheral nitric-oxide mechanism of conventional vasodilators. It continues to be evaluated for its impact on sexual-function modulation, energy regulation, appetite control, and mood balance. Clinical evidence remains limited to small-scale trials; large-scale, long-term studies are required to establish safety, optimal dosing, and sustained outcomes. In Australia, prescribing is restricted to individual compounded supply following consultation under off-label conditions.

Disclaimer

Educational content only; not medical advice.

PT-141 compounded preparations are not registered with the Therapeutic Goods Administration (TGA) and are not approved for any therapeutic claim on this site.

No efficacy or treatment guarantees are made.

All use must occur under consultation and prescription by a registered clinician.
Buy Now, Pay Later with
Earn Points while you Drip with
           

Mobile IV Drip

NAD+ Subcutaneous Pen

NAD+ Subcutaneous injection

NAD+ Infusion

Melbourne NAD+

Brisbane NAD+

Gold Coast NAD+

NAD+ at Home

NAD+

PT-141

Sydney NAD+

NAD+ Injection

NAD+ Australia

BPC-157

Bio-hacking NAD+

anti-aging NAD+

nad+ Injection

Mobile IV drip NAD+

Mobile IV drip NAD+ Melbourne

Mobile IV drip NAD+ Brisbane

Mobile IV drip NAD+ Sydney

Mobile IV drip NAD+ Gold Coast

NAD+ drip at home Melbourne

At home nad+

IV nad

Hydration drip

NAD drip

NAD infusion

IV NAD infusion

NAD drip mobile

NAD IV drip

NAD IV

nad at home

Inject+ Disclaimer

By continuing, you acknowledge and agree to the following terms and conditions of ExclusIV by Mobile IV Drip:

1. Elective Wellness Services
All IV infusions and subcutaneous products offered through Mobile IV Drip are elective wellness services. They are not prescribed or promoted as medically necessary treatments and are designed to support general wellness and vitality.

2. No Public Advertising
The information displayed in this section is provided privately on request and does not constitute public advertising.

3. No Medical or Therapeutic Claims
No statements here should be interpreted as claims of therapeutic benefit. Services and compounded formulations are not a substitute for professional medical advice, prescribed medication, or conventional treatment.

4. Practitioner Review Required
Before any compounded or prescription-only product is supplied, clients are required to complete medical intake and be reviewed by an authorised prescriber and/or nurse practitioner, and obtain a prescription where required.

5. Pricing
Pricing shown is indicative only and may change following clinical assessment, prescription requirements, or compounding variables. Final costs are confirmed after prescriber approval.

6. Voluntary Request
You confirm you are voluntarily requesting this information for personal education, and that access does not guarantee suitability for every option listed.

7. Privacy
Any information you provide may be used to communicate about consultations, prescriptions or updates, with opt-out available.

By selecting “I want ExclusIV access”, you confirm you have read and understood the above.